Accelerate Diagnostics, Inc.

Symbol: AXDX

NASDAQ

0.87

USD

Market price today

  • -0.3038

    P/E Ratio

  • 0.0071

    PEG Ratio

  • 18.85M

    MRK Cap

  • 0.00%

    DIV Yield

Accelerate Diagnostics, Inc. (AXDX) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.18%

Operating Profit Margin

-3.77%

Net Profit Margin

-4.53%

Return on Assets

-1.79%

Return on Equity

1.84%

Return on Capital Employed

-3.14%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Devices
CEO:Mr. Jack Phillips
Full-time employees:134
City:Tucson
Address:3950 South Country Club Road
IPO:1994-04-07
CIK:0000727207

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

General Outlook

When we look at how much money they make before expenses, they keep 0.184% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -3.772%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -4.533%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -1.791% return, is a testament to Accelerate Diagnostics, Inc.'s adeptness in optimizing resource deployment. Accelerate Diagnostics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 1.844%. Furthermore, the proficiency of Accelerate Diagnostics, Inc. in capital utilization is underscored by a remarkable -3.138% return on capital employed.

Stock Prices

Accelerate Diagnostics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.9499, while its low point bottomed out at $0.88. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Accelerate Diagnostics, Inc.'s stock market.

Liquidity Ratios

Analyzing AXDX liquidity ratios reveals its financial health of the firm. The current ratio of 149.61% gauges short-term asset coverage for liabilities. The quick ratio (104.29%) assesses immediate liquidity, while the cash ratio (90.55%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio149.61%
Quick Ratio104.29%
Cash Ratio90.55%

Profitability Ratios

AXDX profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -446.27% underscores its earnings before tax deductions. The effective tax rate stands at -1.57%, revealing its tax efficiency. The net income per EBT, 101.57%, and the EBT per EBIT, 118.32%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -377.16%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-446.27%
Effective Tax Rate-1.57%
Net Income per EBT101.57%
EBT per EBIT118.32%
EBIT per Revenue-377.16%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.50, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 547.63% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding104
Days of Inventory Outstanding120
Operating Cycle186.36
Days of Payables Outstanding188
Cash Conversion Cycle-2
Receivables Turnover5.48
Payables Turnover1.94
Inventory Turnover3.05
Fixed Asset Turnover2.26
Asset Turnover0.40

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -1.84, and free cash flow per share, -1.89, depict cash generation on a per-share basis. The cash per share value, 0.76, showcases liquidity position. Lastly, the operating cash flow sales ratio, -2.91, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-1.84
Free Cash Flow per Share-1.89
Cash per Share0.76
Operating Cash Flow Sales Ratio-2.91
Free Cash Flow to Operating Cash Flow Ratio1.03
Cash Flow Coverage Ratio-0.91
Short Term Coverage Ratio-48.60
Capital Expenditure Coverage Ratio-34.49
Dividend Paid and Capex Coverage Ratio-34.49

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 126.00%, highlights its total liabilities relative to assets. With a debt-equity ratio of -1.50, we discern the balance between debt and equity financing. The long-term debt to capitalization, 311.26%, and total debt to capitalization, 299.40%, ratios shed light on its capital structure. An interest coverage of -11.86 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio126.00%
Debt Equity Ratio-1.50
Long Term Debt to Capitalization311.26%
Total Debt to Capitalization299.40%
Interest Coverage-11.86
Cash Flow to Debt Ratio-0.91
Company Equity Multiplier-1.19

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.97, provides a glimpse into top-line earnings distributed across each share. Net income per share, -4.94, reflects the portion of profit attributed to each share. The book value per share, -1.59, represents the net asset value distributed per share, while the tangible book value per share, -1.59, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.97
Net Income Per Share-4.94
Book Value Per Share-1.59
Tangible Book Value Per Share-1.59
Shareholders Equity Per Share-1.59
Interest Debt Per Share3.70
Capex Per Share-0.08

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -5.43%, indicates top-line expansion, while the gross profit growth, -22.80%, reveals profitability trends. EBIT growth, 13.98%, and operating income growth, 13.98%, offer insights into operational profitability progression. The net income growth, 1.40%, showcases bottom-line expansion, and the EPS growth, 35.09%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-5.43%
Gross Profit Growth-22.80%
EBIT Growth13.98%
Operating Income Growth13.98%
Net Income Growth1.40%
EPS Growth35.09%
EPS Diluted Growth35.09%
Weighted Average Shares Growth51.86%
Weighted Average Shares Diluted Growth51.86%
Operating Cash Flow Growth17.51%
Free Cash Flow Growth16.34%
10-Year Revenue Growth per Share7426.02%
5-Year Revenue Growth per Share-7.11%
3-Year Revenue Growth per Share-51.51%
10-Year Operating CF Growth per Share-24.25%
5-Year Operating CF Growth per Share74.09%
3-Year Operating CF Growth per Share64.19%
10-Year Net Income Growth per Share-21.51%
5-Year Net Income Growth per Share69.53%
3-Year Net Income Growth per Share64.63%
10-Year Shareholders Equity Growth per Share-114.44%
5-Year Shareholders Equity Growth per Share-115.14%
3-Year Shareholders Equity Growth per Share85.79%
Receivables Growth8.53%
Inventory Growth-36.27%
Asset Growth-51.76%
Book Value per Share Growth41.18%
Debt Growth-49.42%
R&D Expense Growth-5.80%
SGA Expenses Growth-20.33%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 75,991,840, captures the company's total value, considering both debt and equity. Income quality, 0.65, assesses the reliability of reported earnings.

cards.indicatorcards.value
Enterprise Value75,991,840
Income Quality0.65
Research and Development to Revenue210.24%
Capex to Operating Cash Flow2.57%
Capex to Revenue-8.58%
Capex to Depreciation-31.81%
Stock-Based Compensation to Revenue44.67%
Graham Number13.31
Return on Tangible Assets-196.45%
Graham Net Net-2.76
Working Capital12,432,000
Tangible Asset Value-19,888,000
Net Current Asset Value-26,788,000
Invested Capital-2
Average Receivables2,519,000
Average Payables4,648,500
Average Inventory4,252,000
Days Sales Outstanding79
Days Payables Outstanding184
Days of Inventory On Hand127
ROIC-296.13%
ROE3.10%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, -0.65, and the price to book ratio, -0.65, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.55, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -0.52, and price to operating cash flows, -0.47, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio-0.65
Price to Book Ratio-0.65
Price to Sales Ratio1.55
Price Cash Flow Ratio-0.47
Price Earnings to Growth Ratio0.01
Enterprise Value Multiple0.12
Price Fair Value-0.65
Price to Operating Cash Flow Ratio-0.47
Price to Free Cash Flows Ratio-0.52
Price to Tangible Book Ratio-2.46
Enterprise Value to Sales6.30
Enterprise Value Over EBITDA-1.50
EV to Operating Cash Flow-1.89
Earnings Yield-125.98%
Free Cash Flow Yield-84.30%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Accelerate Diagnostics, Inc. (AXDX) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.304 in 2024.

What is the ticker symbol of Accelerate Diagnostics, Inc. stock?

The ticker symbol of Accelerate Diagnostics, Inc. stock is AXDX.

What is company IPO date?

IPO date of Accelerate Diagnostics, Inc. is 1994-04-07.

What is company current share price?

Current share price is 0.870 USD.

What is stock market cap today?

The market cap of stock today is 18848028.000.

What is PEG ratio in 2024?

The current 0.007 is 0.007 in 2024.

What is the number of employees in 2024?

In 2024 the company has 134.